Originally marketed for IBS sufferers, it has found a growing audience among GLP-1 users whose primary complaints center on these symptoms
It is not currently listed as a contraindication in UK Summaries of Product Characteristics (SmPCs) for related approved agents, but specialist assessment would be warranted
This straightforward approach typically results in immediate accommodation without personal questions
The trial enrolled 281 participants across 42 research and healthcare centers in the United States, randomized to once-weekly subcutaneous retatrutide (0.5, 4, 8, or 12 mg), once-weekly subcutaneous dulaglutide 1.5 mg (active comparator), or placebo, over a 36-week treatment period
Non-Surgical Skin Tightening Options Not every GLP-1 patient requires surgery to address skin laxity
Pour toute question ou remarque concernant la manire dont nous traitons vos donnes caractre personnel, vous pouvez tout moment nous contacter, soit par e-mail l'adresse [email protected], soit par courrier postal l'une des adresses mentionnes ci-dessus